Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian +36 more·2020·Cancer Cell

DOI 10.1016/j.ccell.2019.12.006

Cited by (477)

Items 101–200 of 477

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
Natalia J. Gurule, Caroline Elizabeth McCoach, Trista K. Hinz, Daniel T. Merrick, Adriaan Van Bokhoven, Jihye Kim, Tejas Patil, Jacob Calhoun, Raphael A. Nemenoff, Aik Choon Tan et al. · 2021 · npj Precision Oncology
Discovery of a cryptic site at the interface 2 of TEAD – Towards a new family of YAP/TAZ-TEAD inhibitors
Manon Sturbaut, Fabrice Bailly, Mathilde Coevoet, Pasquale Sileo, Martine Pugnière, Maxime Liberelle, Romain Magnez, Xavier Thuru, Marie‐Christine Chartier‐Harlin, Patricia Melnyk et al. · 2021 · European Journal of Medicinal Chemistry
Key promoters of tumor hallmarks
Keywan Mortezaee, Jamal Majidpoor · 2021 · International Journal of Clinical Oncology
Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies
Laurence Haddadin, Xueqin Sherine Sun · 2025 · Cells
Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
Mirna Swayden, Houssein Chhouri, Youssef Anouar, Luca Grumolato · 2020 · Cells
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers
Hongge Liang, Yan Xu, Jing Zhao, Minjiang Chen, Mengzhao Wang · 2024 · Cancer Gene Therapy
TEAD4 as an Oncogene and a Mitochondrial Modulator
Sheng‐Chieh Hsu, Ching‐Yu Lin, Yen‐Yi Lin, Colin C. Collins, Chia‐Lin Chen, Hsing‐Jien Kung · 2022 · Frontiers in Cell and Developmental Biology
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse
Mengnuo Chen, Sara Mainardi, Cor Lieftink, Arno Velds, Iris de Rink, Chen Guang Yang, Hendrik J. Kuiken, Ben Morris, Finn Edwards, Fleur Jochems et al. · 2024 · Cell Reports Medicine
Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated
Keywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad · 2022 · Medical Oncology
A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities
Jianfeng Lou, Yuhang Lu, Jing Cheng, Feilong Zhou, Ziqin Yan, Daizhou Zhang, Xiangjing Meng, Yujun Zhao · 2022 · European Journal of Medicinal Chemistry
Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma
Jiaqi Liang, Guoshu Bi, Qihai Sui, Guangyin Zhao, Huan Zhang, Yunyi Bian, Zhencong Chen, Yiwei Huang, Junjie Xi, Yu Shi et al. · 2024 · Cell Reports
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Camille Léonce, Pierre Saintigny, Sandra Ortiz‐Cuaran · 2021 · Molecular Cancer Research
NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation
Rongrong Wu, Arya Mariam Roy, Yoshihisa Tokumaru, Shipra Gandhi, Mariko Asaoka, Masanori Oshi, Li Yan, Takashi Ishikawa, Kazuaki Takabe · 2022 · Cancers
Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation
Dai Cao, Die Chen, Jiang-Nan Xia, Wenyan Wang, Guo‐Yuan Zhu, Liwen Chen, Chuantao Zhang, Bo Tan, Hui Li, Yingwei Li · 2022 · Biomedicine & Pharmacotherapy
Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer
Hirofumi Takahashi, Jun Sakakibara‐Konishi, Megumi Furuta, Tetsuaki Shoji, Kosuke Tsuji, Daisuke Morinaga, Eiki Kikuchi, Junko Kikuchi, Takuro Noguchi, Kanako C. Hatanaka et al. · 2022 · Cancer Science
Tumor dormancy: EMT beyond invasion and metastasis
Patrick Aouad, Hazel M. Quinn, Adeline Berger, Cathrin Brisken · 2023 · genesis
Targeting paraptosis in cancer: opportunities and challenges
Fangquan Chen, Hu Tang, Xiutao Cai, Junhao Lin, Limin Xiang, Rui Kang, Jiao Liu, Daolin Tang · 2024 · Cancer Gene Therapy
Clinical management and biology of tumor dormancy in breast cancer
Stefan Werner, Isabel Heidrich, Klaus Pantel · 2021 · Seminars in Cancer Biology
Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents
Qing Zhou, Xiotian Sun, Nicolas Pasquier, Parvaneh Jefferson, Trang Thi Thu Nguyen, Markus David Siegelin, James M. Angelastro, Lloyd A. Greene · 2021 · Cancers
Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Hui Wang, Qianfan Hu, Yuzhong Chen, Xing Huang, Yipeng Feng, Yuanjian Shi, Rutao Li, Xuewen Yin, Xuming Song, Yingkuan Liang et al. · 2024 · Nature Communications
FZD5 prevents epithelial-mesenchymal transition in gastric cancer
Dan Feng Dong, Na Lei, Kailing Zhou, Zhuo Wang, Yu Sun, Qianqian Zheng, Jian Gao, Chenghai Zhao, Wei Wang · 2021 · Cell Communication and Signaling
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology
Catherine Allison Stewart, Carl Michael Gay, Kavya Ramkumar, Kasey R. Cargill, Robert J. Cardnell, Monique B. Nilsson, Simon Heeke, Elizabeth M. Park, Samrat T. Kundu, Lixia Diao et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR/MAPK pathway and abrogating autophagy in non-small cell lung cancer
Yue Ning, Hongmei Zheng, Yang Yang, Hongjing Zang, Weiyuan Wang, Yuting Zhan, Haihua Wang, Jiadi Luo, Qiuyuan Wen, Jinwu Peng et al. · 2023 · International Journal of Biological Sciences
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Magda Bahcall, Cloud P. Paweletz, Yanan Kuang, Luke J. Taus, Taebo Sim, Nam Doo Kim, Kshiti H. Dholakia, Christie J. Lau, Prafulla C. Gokhale, Pratik R. Chopade et al. · 2021 · Molecular Cancer Therapeutics
Aorta Regulatory T Cells with a Tissue‐Specific Phenotype and Function Promote Tissue Repair through Tff1 in Abdominal Aortic Aneurysms
Jingyong Li, Ni Xia, Dan Li, Shuang Wen, Shirui Qian, Yuzhi Lu, Muyang Gu, Tingting Tang, Jiao Jiao, Bingjie Lv et al. · 2022 · Advanced Science
Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling
Kang‐Yun Lee, Tai-Chih Kuo, Chih-Ming Chou, Wen‐Jing Hsu, Wei-Cheng Lee, Jia-Zih Dai, Sheng‐Ming Wu, Cheng‐Wei Lin · 2020 · Cells
PPA1 Promotes Breast Cancer Proliferation and Metastasis Through PI3K/AKT/GSK3β Signaling Pathway
Chunlei Guo, Shuang Li, Ang Liang, Mengchao Cui, Yunwei Lou, Hui Wang · 2021 · Frontiers in Cell and Developmental Biology
Targeting YAP1 / TAZ in nonsmall‐cell lung carcinoma: From molecular mechanisms to precision medicine
Chun Wai Mui, Wai Nok Chan, Bonan Chen, Alvin H.K. Cheung, Jun Qing Yu, Kwok Wai Lo, Ke Huixing, Wei Kang, Ka Fai To · 2022 · International Journal of Cancer
Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer
Alexander Ring, Maria Spataro, Andreas N. WICKI, Nicola Aceto · 2022 · Frontiers in Cell and Developmental Biology
Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside
Zhile Wang, Mengyao Wang, Bo Dong, Yuqing Wang, Zheyu Ding, Shensi Shen · 2025 · Nature Communications
YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis
Yang, Wang, Zhang, Ming, Zhang, Tian-Xing, Liu, Jia-Hui, Hao, Man-Wei, Yan, Xu, Gao, Haicheng, Lei, Qun-Ying, Cui, Jiuwei, Zhou, Xin · 2024 · JCI Insight
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
Brianna R. Daley, Heidi M. Vieira, Chaitra Rao, Jacob M. Hughes, Zaria Beckley, Dianna H. Huisman, Deepan Chatterjee, Nancy E. Sealover, Katherine Cox, James W. Askew et al. · 2023 · Proceedings of the National Academy of Sciences
Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer
Chun-Hua Hung, Shang‐Yin Wu, Cheng-I Yao, Hsuan-Heng Yeh, Chien‐Chung Lin, Chang‐Yao Chu, Tzu-Yu Huang, Meng‐Ru Shen, Chun‐Hung Lin, Wu‐Chou Su · 2024 · Nature Communications
Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition
Sayantanee Paul, Thijs J. Hagenbeek, Julien Tremblay, Vasumathi Kameswaran, Christy C. Ong, Chad Liu, Alissa D. Guarnaccia, James A. Mondo, Peter Hsu, Noelyn M. Kljavin et al. · 2025 · Nature Communications
Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy
Siyuan Qin, Bowen Li, Hui Ming, Edouard Collins Nice, Bingwen Zou, Canhua Huang · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Z. Liu, Lok-Hei Chan, Jungmin Choi, Mary Ann Melnick, Anna Arnal Estape, Zenta Walther, Dejian Zhao et al. · 2024 · Cancer Research
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics
Lawrence Wen Wu, Sung Joo Jang, Cameron Shapiro, Ladan Fazlollahi, Timothy Cragin Wang, Sandra W. Ryeom, Ryan H. Moy · 2024 · Targeted Oncology
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?
Sayantanee Paul, Jessica Sims, Trang Pham, Anwesha Dey · 2024 · Trends in cancer
Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer
Jingqiang Huang, Ling-Xin Duan, Qiuyu Liu, He-Feng Li, Ao-Ping Hu, Junwei Song, Chuxuan Lin, Bingsheng Huang, Da Yao, Bin Peng et al. · 2023 · Oncogene
C-IGF1R encoded by cIGF1R acts as a molecular switch to restrict mitophagy of drug-tolerant persister tumour cells in non-small cell lung cancer
Hui Wang, Yingkuan Liang, Te Zhang, Xinnian Yu, Xuming Song, Yuzhong Chen, Qixing Mao, Wenjie Xia, Bing Chen, Lin Xu et al. · 2023 · Cell Death and Differentiation
MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
Chao‐Ju Chen, Yu‐Peng Liu · 2021 · Pharmaceuticals
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
Kenichi Suda, Tetsuya Mitsudomi · 2021 · Cells
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
Célia Delahaye, Sarah Figarol, Anne Pradines, Gilles Favre, Julien Mazières, Olivier Calvayrac · 2022 · Cancers
Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
María E.R. García-Rendueles, Gnana Prakasam Krishnamoorthy, Mahesh Saqcena, Adrián Acuña-Ruíz, Giovanna Revilla, Elisa de Stanchina, Jeffrey A. Knauf, Rona Lester, Bin Xu, Ronald A. Ghossein et al. · 2022 · Molecular Cancer
STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway
Hui Xu, Xiaomei Yang, Xiaofeng Xuan, Di Wu, Jieru Zhang, Xinchun Xu, Yuanjie Zhao, Chunping Ma, Dawei Li · 2021 · Neoplasia
UM-6 induces autophagy and apoptosis via the Hippo-YAP signaling pathway in cervical cancer
Dongying Wang, Jiaxing He, Junxue Dong, Shuying Wu, Shanshan Liu, He Zhu, Tianmin Xu · 2021 · Cancer Letters
Oncogenic Pathways in Neurodegenerative Diseases
Luis Varela, María E.R. García-Rendueles · 2022 · International Journal of Molecular Sciences
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Akira Ooki, Hiroki Osumi, Keisho Chìn, Masayuki Watanabe, Kensei Yamaguchi · 2023 · Therapeutic Advances in Medical Oncology
AXL activates YAP through the EGFR–LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma
Kento Okamoto, Toshinori Ando, Hiroki Izumi, Susumu S. Kobayashi, Tomoaki Shintani, Jorge Silvio Gutkind, Souichi Yanamoto, Mutsumi Miyauchi, Mikihito Kajiya · 2023 · Oncogene
Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
Xiao-Hai Song, Lan Yang, Xiuli Zheng, Qianyu Zhu, Xu-Liang Liao, Kai Liu, Weihan Zhang, Qunyong Peng, Yunfeng Zhu, Lin-Yong Zhao et al. · 2023 · MedComm
Matrix stiffness induces an invasive-dormant subpopulation via cGAS-STING axis in oral cancer
Li Jingyuan, Yu Liu, Hong Jiang, Tao Wang, Kan Li, Xiaomei Lao, Liao Guiqing, Liang Yujie · 2023 · Translational Oncology
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer
Jian Zhang, Kejia Zhao, Wenjing Zhou, Ran Kang, Shiyou Wei, Yueli Shu, Yu Cheng, Yin Ku, Yonghong Mao, Hao Luo et al. · 2024 · Signal Transduction and Targeted Therapy
It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma
Rebeca Yakubov, Ramneet Kaloti, Phooja Persaud, Anna McCracken, Gelareh Mohammed Zadeh, Severa Bunda · 2025 · Journal of Neuro-Oncology
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry
Laura Scalvini, Riccardo Castelli, Silvia La Monica, Marcello Tiseo, Roberta R Alfieri · 2021 · Biochemical Pharmacology
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
Yoshihisa Kobayashi, Geoffrey R. Oxnard, Elizabeth F. Cohen, Navin R. Mahadevan, Joao V. Alessi, Yin Pun Hung, Arrien A. Bertram, David E. Heppner, Maurício Fernando Silva Almeida Ribeiro, Karina Perez Sacardo et al. · 2022 · Nature Communications
Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer
Piera Tocci, Roberta Cianfrocca, Rosanna Sestito, Laura Rosanò, Valeriana Di Castro, Giovanni Blandino, Anna Bagnato · 2020 · Cancer Letters
Targeting the Hippo/ YAP / TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers
Alexander Howard, Jodie Bojko, Benjamin P. Flynn, Sophie Bowen, Ute Jungwirth, Gernot Walko · 2022 · Experimental Dermatology
Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer
Motohiro Izumi, Masanori Fujii, Ikei S. Kobayashi, Vivian Ho, Yukie Kashima, Hibiki Udagawa, Daniel Botelho Costa, Susumu S. Kobayashi · 2024 · Cell Death and Disease
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
Jii Bum Lee, Sujin Choi, Hyo Sup Shim, Byung Jo Park, Chang Young Lee, Sumedha Sudhaman, Sharlene Velichko, Min Hee Hong, Byoung Chul Cho, Sun Min Lim · 2024 · Journal of Thoracic Oncology
Leveraging Hot Spots of TEAD–Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling
Bin Zhao, Ajaybabu V. Pobbati, Brian P. Rubin, Shaun R. Stauffer · 2023 · Pharmaceuticals
The origins of cancer cell dormancy
Morales-Valencia, Jorge, David, Gregory · 2022 · Current Opinion in Genetics & Development
The premise of personalized immunotherapy for cancer dormancy
Masoud H. Manjili · 2020 · Oncogene
Hsa_circ_0007312 Promotes Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance through Pyroptosis and Apoptosis via the MiR-764/MAPK1 Axis in Lung Adenocarcinoma Cells
Chenyue Dai, Zeming Ma, Jiahui Si, Guo An, Wenlong Zhang, Shaolei Li, Yuanyuan Ma · 2022 · Journal of Cancer
Autophagy Inhibition Contributes to Apoptosis of PLK4 Downregulation-induced Dormant Cells in Colorectal Cancer
Xiangdong Tian, Yuchao He, Lisha Qi, Dongming Liu, Dejun Zhou, Yun Liu, Wenchen Gong, Zhiqiang Han, Yuren Xia, Hua Li et al. · 2023 · International Journal of Biological Sciences
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
Danlei Yu, Wen Zhao, Karin A. Vallega, Shi‐Yong Sun · 2021 · Lung Cancer Targets and Therapy
DNMT1 determines osteosarcoma cell resistance to apoptosis by associatively modulating DNA and mRNA cytosine‐5 methylation
Dongxing Shao, Cihang Liu, Yingying Wang, Lin Jing, Xiaolei Cheng, Pei Han, Zhen Li, Dongdong Jian, Junwei Nie, Mingyang Jiang et al. · 2023 · The FASEB Journal
Analyzing embryo dormancy at single-cell resolution reveals dynamic transcriptional responses and activation of integrin-Yap/Taz prosurvival signaling
Rui Chen, Rui Fan, Fei Chen, Niraimathi Govindasamy, Heike Brinkmann, Martin Stehling, Ralf H. Adams, Hyun‐Woo Jeong, Ivan Bedzhov · 2024 · Cell stem cell
Cell enlargement modulated by GATA4 and YAP instructs the senescence-associated secretory phenotype
Joae Joung, Yekang Heo, Yeonju Kim, Jae‐Jin Kim, Haebeen Choi, Taerang Jeon, Yeji Jang, Eun-Jung Kim, Sang Heon Lee, Jae Myoung Suh et al. · 2025 · Nature Communications
Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
Paul Dent, Laurence A. Booth, Andrew Stewart Poklepovic, Daniel D. Von Hoff, Jennifer Martinez, Yong Zhou, John F. Hancock · 2021 · Biochemical Pharmacology
Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs
Maxime Liberelle, Florine Toulotte, Nicolas Renault, Muriel Gelin, Frédéric Allemand, Patricia Melnyk, Jean‐François Guichou, Philippe Cotelle · 2022 · Journal of Medicinal Chemistry
DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis
Sunwang Xu, Zhiqing Yuan, Cen Jiang, Wei Chen, Qiwei Li, Tao Chen · 2024 · Advanced Science
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer
Majid Momeny, Mari Tienhaara, Mukund Sharma, Deepankar Chakroborty, Roosa Varjus, Iina Takala, Joni Merisaari, Artur Padzik, Andreas Vogt, Ilkka Paatero et al. · 2024 · EMBO Molecular Medicine
Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib‑resistant non‑small cell lung cancer cells
Yang� Yang, Yizhe Wang, Xiaofang Che, Kezuo Hou, Jie Wu, Chunlei Zheng, Cheng Hsun Yang, Yunpeng Liu, Xuejun Hu, Jingdong Zhang · 2021 · Oncology Letters
Breast cancer dormancy is associated with a 4NG1 state and not senescence
Chloé Prunier, Ania Alay, Michiel van Dijk, Kelly L. Ammerlaan, Sharon van Gelderen, Dieuwke Louise Marvin, Amina F.A.S. Teunisse, Roderick C. Slieker, Károly Szuhai, Aart G. Jochemsen et al. · 2021 · npj Breast Cancer
Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens
Inês Amorim Monteiro Barbosa, Rajaraman Gopalakrishnan, Samuele Mercan, Thanos P. Mourikis, Typhaine Martin, Simon Wengert, Caibin Sheng, Fei Ji, Rui Lopes, Judith Knehr et al. · 2023 · Nature Communications
Transforming cancer cells for long-term living with cancer: An inspiring new approach
Mingjie Jiang, Dian-na Gu, Fu-Rao Liu, Chen-jing Lin, Ling Tian · 2023 · Chinese Journal of Cancer Research
Pharmacological regulators of Hippo pathway: Advances and challenges of drug development
Zhaobai Lao, Xin Chen, Bin Pan, Bin Fang, Wanlei Yang, Yu Qian · 2025 · The FASEB Journal
Discovery of Dioxo-Benzo[b]Thiophene Derivatives as Potent YAP-TEAD Interaction Inhibitors for Treating Breast Cancer
Youngchai Son, Jaeyeal Kim, Yong‐Chan Kim, Sung-Gil Chi, Tackhoon Kim, Jinha Yu · 2022 · Bioorganic Chemistry
Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase
Ruihua Liu, Shang Su, Jing Xing, Ke Liu, Yawei Zhao, Mary M. Stangis, Diego Jacho, Eda D. Yildirim-Ayan, Cara M. Gatto-Weis, Bin Chen et al. · 2023 · Journal of Experimental & Clinical Cancer Research
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies
Sarah Figarol, Célia Delahaye, Rémi Gence, Aurélia Doussine, Juan‐Pablo Cerapio, Mathylda Brachais, Claudine Tardy, Nicolas Béry, Raghda Asslan, Jacques Colinge et al. · 2024 · Nature Communications
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Yohei Matsui, Soichi Hirai, Masaki Ishida, Hayato Kawachi, Ryo Sawada et al. · 2024 · Cancer Letters
Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
Keigo Kobayashi, Aaron C. Tan · 2023 · International Journal of Molecular Sciences
Current landscape of targeted therapy in esophageal squamous cell carcinoma
Amane Jubashi, Daisuke Kotani, Takashi Kojima, Naoko Takebe, Kohei Shitara · 2024 · Current Problems in Cancer
Selective Degradation of TEADs by a PROTAC Molecule Exhibited Robust Anticancer Efficacy In Vitro and In Vivo
Yuhang Lu, Ziqin Yan, Jiaqi Sun, Chenxu Wang, Lan Xu, Xilin Lyu, Xiancheng Wang, Jianfeng Lou, He Huang, Linghua Meng et al. · 2025 · Journal of Medicinal Chemistry
Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Vindhya Vijay, Negin Karisani, Lei Shi, Yu-Han Hung, Phuong Vu, Prabhat Kattel, Lauren Kenney, Joshua Merritt, Ramzi Adil, Qibiao Wu et al. · 2025 · Cancer Discovery
Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC
Céline Mascaux, Triparna Sen, Montse Sánchez‐Céspedes, Sandra Ortiz‐Cuaran, Yohan Bossé, Floris F. Dammeijer, Milena R. Cavic, Martin P. Barr, Surein Arulananda, Ricardo Armisén et al. · 2025 · Journal of Thoracic Oncology
Phospholipase C Delta 3 inhibits apoptosis and promotes proliferation, migration, and invasion of thyroid cancer cells via Hippo pathway
Lizhi Lin, Jialiang Wen, Bangyi Lin, Hao Chen, Adheesh Bhandari, Yufeng Qi, Danni Zheng, Ouchen Wang · 2021 · Acta Biochimica et Biophysica Sinica
Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe
Guoxin Zhang, Zhen Dong, Ryan C. Gimple, Arthur R. Wolin, Qiulian Wu, Zhixin Qiu, Lisa M. Wood, Jia Shen, Li Jiang, Linjie Zhao et al. · 2021 · The Journal of Experimental Medicine
Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation
Yimin Li, Yaqi Li, Chao Ning, Jianda Yue, Cheng Zhang, Xiao Dong He, Ying Wang, Zhonghua Liu · 2022 · Computational Biology and Chemistry
Targeting cancer stem cell pathways for lung cancer therapy
Mingxin Liu, Hong Wu, Chuan Shan Xu · 2022 · Current Opinion in Oncology
EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
Akihiko Shiiya, Takuro Noguchi, Utano Tomaru, Shin Ariga, Yuta Takashima, Yoshihito Ohhara, Jun Taguchi, Satoshi Takeuchi, Yasushi Shimizu, Ichiro Kinoshita et al. · 2022 · Cancer Science
Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence
Bashar A. Alhasan, Marina A. Mikeladze, Irina V. Guzhova, Boris A. Margulis · 2023 · Cancer and Metastasis Reviews
Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review
Xian-Wen Liang, Bing Liu, Jia-Cheng Chen, Zhi Wei Cao, Feng-Ran Chu, Lin Xiong, Sheng-Zhong Wang, Jincai Wu · 2023 · Frontiers in Oncology
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
K. Furugaki, Takaaki Fujimura, Hayato Mizuta, T. Yoshimoto, Takashi Asakawa, Y. Yoshimura, S. Yoshiura · 2023 · npj Precision Oncology
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure
Da Hyun Kang, Jisoo Lee, Subin Im, Chaeuk Chung · 2024 · Cancers
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer
Pınar Ö. Eser, Raymond M. Paranal, Jieun Son, Elena V. Ivanova, Yanan Kuang, Heidi M. Haikala, Ciric To, Jeffrey J. Okoro, Kshiti H. Dholakia, Jihyun Choi et al. · 2021 · Science Translational Medicine
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
Tammaccaro, Salvina Laura, Prigent, Philippe, Le Bail, Jean-Christophe, Dos-Santos, Odette, Dassencourt, Laurent, Eskandar, Myriam, Buzy, Armelle, Venier, Olivier, Guillemot, Jean-Claude, Veeranagouda, Yaligara et al. · 2023 · Pharmaceuticals
Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer
Bengisu Dayanc, Sude Eris, Nazife Ege Gulfirat, Gülden Özden-Yılmaz, Ece Çakıroğlu, Ozlem Silan Coskun Deniz, Gökhan Karakülah, Serap Erkek, Şerif Şentürk · 2025 · Cell Death and Disease
Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR -Mutant Lung Cancer
Tongyan Liu, Shiyi Huang, Zhitong Li, Jianyu Li, Qinhong Sun, Qinglin Wang, Ziyang Shen, Zhijun Xia, Fanchen Meng, Youtao Xu et al. · 2025 · Cancer Research
Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy
Masahiro Shibata, Akira Ooki, Yoshikuni Inokawa, Pritam Sadhukhan, M. Talha Ugurlu, Evgeny Izumchenko, Enrico Munari, Giuseppe Salvatore Bogina, Charles M. Rudin, Edward Gabrielson et al. · 2020 · Molecular Cancer Therapeutics